0000899243-20-003364.txt : 20200205 0000899243-20-003364.hdr.sgml : 20200205 20200205175928 ACCESSION NUMBER: 0000899243-20-003364 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200203 FILED AS OF DATE: 20200205 DATE AS OF CHANGE: 20200205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bolzon Bradley J PhD CENTRAL INDEX KEY: 0001354345 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 20580150 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-03 0 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001354345 Bolzon Bradley J PhD C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2020-02-03 4 C 0 4973787 A 5305372 I See footnote Common Stock 2020-02-03 4 C 0 380817 A 380817 I See footnote Common Stock 2020-02-03 4 C 0 1277111 A 1277111 I See footnote Common Stock 2020-02-03 4 C 0 653412 A 5958784 I See footnote Common Stock 2020-02-03 4 C 0 150085 A 530902 I See footnote Common Stock 2020-02-03 4 C 0 503327 A 1780438 I See footnote Common Stock 2020-02-03 4 C 0 810522 A 810522 I See footnote Common Stock 2020-02-03 4 C 0 454548 A 6413332 I See footnote Common Stock 2020-02-03 4 C 0 104407 A 635309 I See footnote Common Stock 2020-02-03 4 C 0 350141 A 2130579 I See footnote Common Stock 2020-02-03 4 P 0 79013 19.00 A 2209592 I See footnote Common Stock 2020-02-03 4 P 0 23560 19.00 A 658869 I See footnote Common Stock 2020-02-03 4 P 0 396082 19.00 A 6809414 I See footnote Common Stock 2020-02-03 4 P 0 396081 19.00 A 1206603 I See footnote Series A Preferred Stock 2020-02-03 4 C 0 15000000 D Common Stock 4973787 0 I See footnote Series A Preferred Stock 2020-02-03 4 C 0 1148474 D Common Stock 380817 0 I See footnote Series A Preferred Stock 2020-02-03 4 C 0 3851526 D Common Stock 1277111 0 I See footnote Series B Preferred Stock 2020-02-03 4 C 0 1970572 D Common Stock 653412 0 I See footnote Series B Preferred Stock 2020-02-03 4 C 0 452630 D Common Stock 150085 0 I See footnote Series B Preferred Stock 2020-02-03 4 C 0 1517940 D Common Stock 503327 0 I See footnote Series C Preferred Stock 2020-02-03 4 C 0 2444382 D Common Stock 810522 0 I See footnote Series C Preferred Stock 2020-02-03 4 C 0 1370833 D Common Stock 454548 0 I See footnote Series C Preferred Stock 2020-02-03 4 C 0 314873 D Common Stock 104407 0 I See footnote Series C Preferred Stock 2020-02-03 4 C 0 1055960 D Common Stock 350141 0 I See footnote Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). The Reporting Person may be deemed to beneficially own indirectly 810,522 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. On February 3, 2020, Versant Voyageurs I purchased 79,013 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On February 3, 2020, Versant I Parallel purchased 23,560 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On February 3, 2020, Versant VI purchased 396,082 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On February 3, 2020, Versant Vantage I purchased 396,081 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. /s/ Brent Hatzis-Schoch, as Attorney-in-Fact 2020-02-05